NCT00325936

The Effects of Cilnidipine on Metabolic Syndrome Improvement

A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS]

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 186 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 30 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with hypertension, and these metabolic abnormalities are reported to be related to insulin resistance. Therefore, whenever treating such patients, antihypertensive agents that may have the added effect of improving insulin resistance should be selected. CinalongTM (Cilnidipine) is expected to improve metabolic syndrome as well as insulin resistance by its dual effects on L and N-type calcium (Ca) channels. In this study, the researchers investigate the effects of CinalongTM on insulin resistance and other metabolic related factors.

Detailed description

* Multi-center, randomized, prospective, double blind, active control, parallel study * Superiority study (Treatment group - Cilnidipine/Control group - Nifedipine) * Measure the effects of Cinalong(TM) after 3 month and 12 month-application

Conditions

• Hypertension
• Metabolic Syndrome X

Interventions

Type	Name	Description
DRUG	Cilnidipine	10\~20mg, qd, po for 3 months or 12 months.

Timeline

• Start date: 2005-07-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2006-05-15
• Last updated: 2008-08-27

Locations

1 site across 1 country: South Korea